HUP0303126A3 - Vectors for molecule delivery to cd11b expressing cells - Google Patents
Vectors for molecule delivery to cd11b expressing cellsInfo
- Publication number
- HUP0303126A3 HUP0303126A3 HU0303126A HUP0303126A HUP0303126A3 HU P0303126 A3 HUP0303126 A3 HU P0303126A3 HU 0303126 A HU0303126 A HU 0303126A HU P0303126 A HUP0303126 A HU P0303126A HU P0303126 A3 HUP0303126 A3 HU P0303126A3
- Authority
- HU
- Hungary
- Prior art keywords
- vectors
- expressing cells
- molecule delivery
- cd11b expressing
- cd11b
- Prior art date
Links
- 239000013598 vector Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01001—Aodenylate cyclase (4.6.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00402562A EP1188446B1 (en) | 2000-09-15 | 2000-09-15 | Proteinaceous vectors for molecule delivery to CD11b expressing cells |
| PCT/EP2001/011315 WO2002022169A2 (en) | 2000-09-15 | 2001-09-14 | VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0303126A2 HUP0303126A2 (hu) | 2003-12-29 |
| HUP0303126A3 true HUP0303126A3 (en) | 2004-10-28 |
Family
ID=8173866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0303126A HUP0303126A3 (en) | 2000-09-15 | 2001-09-14 | Vectors for molecule delivery to cd11b expressing cells |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20040001867A1 (https=) |
| EP (2) | EP1188446B1 (https=) |
| JP (1) | JP2004508065A (https=) |
| KR (2) | KR100953364B1 (https=) |
| AT (2) | ATE438409T1 (https=) |
| AU (2) | AU9385501A (https=) |
| BR (1) | BR0113915A (https=) |
| CA (1) | CA2422603A1 (https=) |
| CZ (1) | CZ2003726A3 (https=) |
| DE (1) | DE60042687D1 (https=) |
| ES (1) | ES2331348T3 (https=) |
| HU (1) | HUP0303126A3 (https=) |
| PL (1) | PL208864B1 (https=) |
| PT (1) | PT1188446E (https=) |
| RU (1) | RU2312143C2 (https=) |
| WO (1) | WO2002022169A2 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646776B1 (fr) | 1989-05-12 | 1994-06-03 | Pasteur Institut | Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella |
| ES2331348T3 (es) | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
| EP1489092A1 (en) * | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
| JP2008500271A (ja) * | 2003-10-14 | 2008-01-10 | ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン | 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ |
| EP2193804B1 (en) | 2003-11-21 | 2015-12-23 | Institut Pasteur | Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens |
| PL1576967T3 (pl) | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| ES2291071B1 (es) * | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| ES2331271B1 (es) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas. |
| CN102046196B (zh) * | 2008-05-29 | 2014-07-30 | 特朗斯吉有限公司 | 用于选择患者的生物标志物及相关方法 |
| CN102439146A (zh) | 2009-03-23 | 2012-05-02 | 巴斯德研究院 | 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物 |
| PL2233569T3 (pl) | 2009-03-23 | 2015-02-27 | Pasteur Institut | Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki |
| GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| EP2478915A1 (en) * | 2011-01-24 | 2012-07-25 | Genticel | CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses |
| EP2690172A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses |
| EP2689786A1 (en) | 2012-07-23 | 2014-01-29 | Genticel | HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders |
| EP2975120A1 (en) | 2014-07-17 | 2016-01-20 | Institut Pasteur | Monomeric and functional adenylate cyclase CyaA toxin |
| EP3323426A1 (en) | 2016-11-17 | 2018-05-23 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
| WO2018091613A1 (en) | 2016-11-17 | 2018-05-24 | Ecole Nationale Vétérinaire de Toulouse | Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection |
| EP3342421A1 (en) | 2016-12-27 | 2018-07-04 | Genticel | Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response |
| US20200255531A1 (en) * | 2017-11-03 | 2020-08-13 | Mackay Memorial Hospital | Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597605B1 (fr) * | 1986-04-16 | 1989-06-23 | Merieux Inst | Nouveau materiau pour chromatographie d'affinite et son application a la separation et a la purification des antigenes proteiques des bacteries du genre bordetella |
| FR2601679B1 (fr) * | 1986-07-15 | 1990-05-25 | Sanofi Sa | Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant |
| US5182211A (en) | 1987-08-07 | 1993-01-26 | Institut Pasteur | Plasmid vectors encoding a protein of a picornavirus |
| US5312902A (en) | 1988-06-09 | 1994-05-17 | Institut Pasteur | Dimer of the precursor of HIV-2 envelope glycoprotein |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| FR2638169B1 (fr) | 1988-10-25 | 1991-01-11 | Pasteur Institut | Derives d'adenyl cyclase et leurs utilisations biologiques |
| EP0406857B1 (en) | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
| NO175188C (no) | 1990-06-27 | 1994-09-14 | Sjur Olsnes | Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol |
| US5935580A (en) * | 1992-04-21 | 1999-08-10 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
| WO1993021324A1 (en) * | 1992-04-21 | 1993-10-28 | Institut Pasteur | Recombinant mutants for inducing specific immune responses |
| JP4256932B2 (ja) * | 1995-06-07 | 2009-04-22 | ジョエル ケイ． スワデッシュ | 抗原プロセシング細胞標的複合体 |
| US5821122A (en) | 1995-06-07 | 1998-10-13 | Inserm (Institute Nat'l De La Sante Et De La Recherche . .) | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
| AU2322097A (en) | 1996-03-27 | 1997-10-17 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| US6333154B1 (en) * | 1997-12-04 | 2001-12-25 | Institut Pasteur | Bacterial multi-hybrid system and applications thereof |
| US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
| CN100352921C (zh) * | 1999-05-06 | 2007-12-05 | 威克福雷大学 | 用于鉴定引起免疫反应的抗原的组合物和方法 |
| CN1402782A (zh) | 1999-10-19 | 2003-03-12 | 路德维哥癌症研究院 | Mage－a12抗原肽及其应用 |
| ES2331348T3 (es) | 2000-09-15 | 2009-12-30 | Pasteur Institut | Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b. |
| EP1489092A1 (en) | 2003-06-18 | 2004-12-22 | Institut Pasteur | Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof |
| JP2008500271A (ja) | 2003-10-14 | 2008-01-10 | ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン | 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ |
| US20070026022A1 (en) | 2004-11-19 | 2007-02-01 | Gilles Dadaglio | Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens |
| EP2193804B1 (en) | 2003-11-21 | 2015-12-23 | Institut Pasteur | Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens |
| PL1576967T3 (pl) | 2004-03-18 | 2008-03-31 | Pasteur Institut | Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne |
| EP1894941A1 (en) | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
| US8017132B2 (en) * | 2009-03-23 | 2011-09-13 | Institut Pasteur | Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell |
-
2000
- 2000-09-15 ES ES00402562T patent/ES2331348T3/es not_active Expired - Lifetime
- 2000-09-15 DE DE60042687T patent/DE60042687D1/de not_active Expired - Lifetime
- 2000-09-15 AT AT00402562T patent/ATE438409T1/de active
- 2000-09-15 EP EP00402562A patent/EP1188446B1/en not_active Expired - Lifetime
- 2000-09-15 PT PT00402562T patent/PT1188446E/pt unknown
-
2001
- 2001-09-14 KR KR1020087015164A patent/KR100953364B1/ko not_active Expired - Fee Related
- 2001-09-14 EP EP01974315A patent/EP1317282B1/en not_active Expired - Lifetime
- 2001-09-14 RU RU2003110574/13A patent/RU2312143C2/ru not_active IP Right Cessation
- 2001-09-14 AU AU9385501A patent/AU9385501A/xx active Pending
- 2001-09-14 CZ CZ2003726A patent/CZ2003726A3/cs unknown
- 2001-09-14 BR BR0113915-0A patent/BR0113915A/pt not_active IP Right Cessation
- 2001-09-14 WO PCT/EP2001/011315 patent/WO2002022169A2/en not_active Ceased
- 2001-09-14 PL PL365743A patent/PL208864B1/pl unknown
- 2001-09-14 AT AT01974315T patent/ATE518880T1/de not_active IP Right Cessation
- 2001-09-14 HU HU0303126A patent/HUP0303126A3/hu unknown
- 2001-09-14 JP JP2002526418A patent/JP2004508065A/ja active Pending
- 2001-09-14 KR KR1020037003818A patent/KR100879151B1/ko not_active Expired - Fee Related
- 2001-09-14 CA CA002422603A patent/CA2422603A1/en not_active Abandoned
- 2001-09-14 AU AU2001293855A patent/AU2001293855B2/en not_active Ceased
-
2003
- 2003-03-14 US US10/387,486 patent/US20040001867A1/en not_active Abandoned
-
2005
- 2005-04-05 US US11/098,404 patent/US20050238637A1/en not_active Abandoned
-
2011
- 2011-06-27 US US13/169,605 patent/US9370564B2/en not_active Expired - Fee Related
-
2016
- 2016-06-08 US US15/177,029 patent/US10004794B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| RU2312143C2 (ru) | 2007-12-10 |
| BR0113915A (pt) | 2003-07-01 |
| US20050238637A1 (en) | 2005-10-27 |
| WO2002022169A3 (en) | 2002-11-21 |
| ATE438409T1 (de) | 2009-08-15 |
| DE60042687D1 (de) | 2009-09-17 |
| HK1057989A1 (en) | 2004-04-30 |
| AU2001293855B2 (en) | 2007-04-26 |
| EP1188446B1 (en) | 2009-08-05 |
| PL208864B1 (pl) | 2011-06-30 |
| KR100879151B1 (ko) | 2009-01-19 |
| PT1188446E (pt) | 2009-11-10 |
| PL365743A1 (en) | 2005-01-10 |
| KR20030055265A (ko) | 2003-07-02 |
| AU9385501A (en) | 2002-03-26 |
| WO2002022169A2 (en) | 2002-03-21 |
| CA2422603A1 (en) | 2002-03-21 |
| ATE518880T1 (de) | 2011-08-15 |
| CZ2003726A3 (cs) | 2003-09-17 |
| EP1317282A2 (en) | 2003-06-11 |
| KR100953364B1 (ko) | 2010-04-20 |
| EP1188446A1 (en) | 2002-03-20 |
| US9370564B2 (en) | 2016-06-21 |
| US20040001867A1 (en) | 2004-01-01 |
| HUP0303126A2 (hu) | 2003-12-29 |
| KR20080059684A (ko) | 2008-06-30 |
| US10004794B2 (en) | 2018-06-26 |
| ES2331348T3 (es) | 2009-12-30 |
| EP1317282B1 (en) | 2011-08-03 |
| US20120214206A1 (en) | 2012-08-23 |
| US20160375119A1 (en) | 2016-12-29 |
| JP2004508065A (ja) | 2004-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0303126A3 (en) | Vectors for molecule delivery to cd11b expressing cells | |
| AU2877102A (en) | Small molecule compositions for binding to hsp90 | |
| AU2001264763A1 (en) | Human mesenchymal progenitor cell | |
| AU1154802A (en) | Single cell electroporation | |
| GB2366071B (en) | Structure for connecting battery terminal | |
| AU5250100A (en) | Vector for expressing two foreign genes | |
| GB0006428D0 (en) | Electrochemical cell | |
| IL152799A0 (en) | Methods for delivering polypeptides to cells | |
| AU2001247676A1 (en) | Methods for in vivo diversification of single genes | |
| GB9922360D0 (en) | Improvements relating to pumps | |
| AU2001286809A1 (en) | Genes expressed in the cell cycle | |
| GB0022101D0 (en) | Delivery of substances to cells | |
| AU2001258708A1 (en) | Vectors for dna delivery | |
| AU2002305665A1 (en) | Vector for targeted delivery to cells | |
| AU2003265907A8 (en) | In vivo ssdna expression vectors for altering gene expression | |
| TW463717U (en) | Improved mold structure for shoemaking | |
| GB9930499D0 (en) | Delivery of substances to cells | |
| TW458105U (en) | Connecting structure for skating scooter | |
| GB9910591D0 (en) | Improvements relating to spectacles | |
| GB0018562D0 (en) | Improvements relating to antenna supports | |
| TW458087U (en) | Folding type connecting structure for skating scooter | |
| GB0021876D0 (en) | Improvements to in vivo procedures | |
| TW472720U (en) | Improved folding structure for skating scooter | |
| TW467075U (en) | Improved folding structure for skating scooter | |
| TW467074U (en) | Improved folding structure for skating scooter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |